Sameer S Kadri, M.B.B.S.
Physician Investigator (NonCl)
Infectious Disease, Mass General Research Institute
Infectious Disease, Massachusetts General Hospital
|MBBS Seth G.S. Medical College 2006|
(Dr. Kadri's) research interest lies in infections in the critically ill. He leverages large datasets for epidemiologic investigations on antimicrobial resistance, sepsis, procalcitonin use, smoke inhalation acute lung injury and the role of IVIG in necrotizing fasciitis and granulocyte transfusions in invasive mycoses. His ongoing work includes use of large electronic health record-based repositories to understand the market size for new antibiotics (in collaboration with the US FDA), the impact of early discontinuation of antibiotics in culture negative sepsis and identify more objective candidate ICU performance measures.
He founded and leads the NIH Antimicrobial Resistance Outcomes Research Initiative (NIH–ARORI), a collaborative between the NIH Clinical Center, Intramural NIAID, the CDC and Harvard Medical School. Through this initiative he developed and tested a simple but clinically relevant bedside classification scheme for antimicrobial resistance called “Difficult-to-treat Resistance” or DTR that focuses on non-susceptibility to all first-line antibiotics. He is a peer reviewer for several subspecialty journals and has served as an editor for the Infectious Diseases Clinics of North America issue titled Complex Infectious Disease Issues in the Intensive Care Unit. He has spearheaded investigations that underscore the benefits of dually training in critical care medicine and infectious diseases and is promoting the unique role of critical care providers in combating antimicrobial resistance.